What I've seen is, with ipamorelin, rare, but some people do get anaphylaxis, and it's happened
"FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list." FDA press announcement
Here is our honest, evidence-based answer: BPC-157 Side Effects: What the Evidence Shows BPC-157 has demonstrated an excellent safety profile in over 100 preclinical studies, with no significant toxicity even at very high doses in animal models
The role of glutathione S-transferases (GSTs) in insecticide resistance in crop pests and disease vectors
3 News-Medical / Metabolic pressCoverage of the AOD-9604 Phase 2b obesity trial outcome (development discontinued ~2007)
This uncertainty is the core reason systemic use cannot be considered well characterized